Ophthalmic surgery, lasers & imaging retina · 2025
Estimated Five-year Risk of Systemic Cardiovascular Events With Anti-VEGF Injections in Neovascular Age-related Macular Degeneration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chong David D, Yue Sophie C, Raynor James L, Murray Isaiah, Chuchta Thomas G, Markle Jonathan C, Shaia Jacqueline K, Singh Rishi P, Talcott Katherine E
Аннотация
BACKGROUND AND OBJECTIVE: To assess 5-year risk for stroke, myocardial infarction (MI), and mortality in patients with neovascular age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor (anti-VEGF) injections compared to patients with geographic atrophy (GA).
PATIENTS AND METHODS: A retrospective cohort study was conducted involving 2,923 patients aged ≥ 50 years, diagnosed with nAMD or GA prior to 2019. There were two cohorts: those receiving anti-VEGF for nAMD and those with GA. A 1:1 greedy matching algorithm matched demographics, comorbidities, and medications. Risk ratios (RR) with 95% confidence intervals (CI) were calculated for primary outcomes.
RESULTS: After matching, there were 1,065 patients in each cohort. No significant differences were observed in risks for ischemic stroke (RR = 1.24, 95% CI [0.91, 1.70]), hemorrhagic stroke (RR = 0.95, [0.52, 1.92]), MI (RR = 0.98, [0.70, 1.39]), or mortality (RR = 1.00, [0.83, 1.19]).
CONCLUSION: Our findings suggest anti-VEGF therapy for nAMD does not increase the risk of stroke, MI, or mortality compared to patients with GA.
PATIENTS AND METHODS: A retrospective cohort study was conducted involving 2,923 patients aged ≥ 50 years, diagnosed with nAMD or GA prior to 2019. There were two cohorts: those receiving anti-VEGF for nAMD and those with GA. A 1:1 greedy matching algorithm matched demographics, comorbidities, and medications. Risk ratios (RR) with 95% confidence intervals (CI) were calculated for primary outcomes.
RESULTS: After matching, there were 1,065 patients in each cohort. No significant differences were observed in risks for ischemic stroke (RR = 1.24, 95% CI [0.91, 1.70]), hemorrhagic stroke (RR = 0.95, [0.52, 1.92]), MI (RR = 0.98, [0.70, 1.39]), or mortality (RR = 1.00, [0.83, 1.19]).
CONCLUSION: Our findings suggest anti-VEGF therapy for nAMD does not increase the risk of stroke, MI, or mortality compared to patients with GA.
Предметные рубрики MeSH
HumansRetrospective StudiesMaleFemaleAngiogenesis InhibitorsIntravitreal InjectionsAgedVascular Endothelial Growth Factor AWet Macular DegenerationMiddle AgedRanibizumabAged, 80 and overFollow-Up StudiesCardiovascular DiseasesRisk FactorsBevacizumabRisk AssessmentTime FactorsIncidenceMyocardial Infarction